Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
|Articles|September 22, 2016
EpiPen Controversy: Mylan CEO Faces Congressional Committee
Author(s)Pharmaceutical Technology
September 22, 2016
Advertisement
Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.
In her
For the rest of this news release, see
Advertisement
Related to this article
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
FDA Pauses Commissioner’s National Priority Voucher Program: Report
3
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
4
Building Connected AI Ecosystems, Not Standalone Tools
5